search for




KCI

Crossref

Cross mark

Cited-by

Fundref

TDM

View (188) Download (208) CrossRef (0)
Korean Clinical Practice Guideline for Smoking Cessation Provided by the National Health Insurance Services
J Korean Soc Res Nicotine Tob 2023; 14(2): 41-48
Published online June 30, 2023
© 2023 The Korean Society for Research on Nicotine and Tobacco.

Yoo Bin Seo1, Yu-Jin Paek2*, Cheol Min Lee3*, Eon Sook Lee4, Hye Seon Kang5, Soo Young Kim6, Sungwon Roh7, Dong Won Park8, Yoo Suk An9, Sang-Ho Jo10; The Guideline Development Group for Developing the Korean Clinical Practice Guideline for Tobacco Cessation

1Department of Family Medicine, Wonkwang University Sanbon Hospital, Gunpo, 2Department of Family Medicine and Health Promotion Center, Hallym University Sacred Heart Hospital, Anyang, 3Department of Family Medicine, Seoul National University Hospital Healthcare System, Gangnam Center, Seoul, 4Department of Family Medicine, Inje University, Ilsan Paik Hospital, Goyang, 5Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary’s Hospital, Bucheon, 6Department of Family Medicine, Kangdong Sacred Heart Hospital, Hallym University Hospital, Seoul, 7Department of Psychiatry, Hanyang University Hospital, Seoul, 8Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, 9Department of Psychiatry, Seoul National University Hospital, Seoul, 10Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart, Anyang, Korea
Correspondence to: *백유진
한림대학교 성심병원 가정의학과
E-mail: noliaa@naver.com
ORCID: https://orcid.org/0000-0001-9573-8849
*이철민
서울대학교병원 강남센터 가정의학과
E-mail: bigbangx@snuh.org
ORCID: https://orcid.org/0000-0001-8652-4355
Received June 2, 2023; Revised June 16, 2023; Accepted June 22, 2023.
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, dis-tribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Background: An evidence-based guideline was formed that addresses several questions regarding pharmacotherapy for smoking cessation among tobacco-dependent adults.
Methods: The multidisciplinary guideline panel selected seven clinical key questions and adopted the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT methodology. The recommendations were verified through literature search and selection, evidence synthesis and evaluation, and the recommendation grade selection process.
Results: For smoking cessation in general population, our recommendation is to use varenicline rather than the nicotine patch or bupropion. We conditionally suggest combining varenicline with a nicotine patch instead of using varenicline alone. As for the duration of treatment, we recommend using extended-duration therapy (more than 12 weeks) rather than standard-duration therapy (6-12 weeks). For tobacco-dependent adults who are not yet ready to quit smoking, we recommend initiating treatment with varenicline rather than waiting for them to be ready. In special populations, for adults with a comorbid psychiatric condition, varenicline is preferred over the nicotine patch. Additionally, pharmacotherapy is strongly recommended for adults with chronic obstructive pulmonary disease.
Conclusion: Seven recommendations that focused on drug treatment for smoking cessation were developed. Moreover, the guideline panel expects that following these guidelines will increase the effectiveness of smoking cessation intervention.
Keywords : Smoking cessation; Practice guideline; Pharmacotherapy
References
  1. Collaborators GT. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet (London, England). 2021; 397(10292): 2337.
    CrossRef
  2. World Health Organization. WHO Framework Convention on Tobacco Control: guidelines for implementation. Geneva, World Health Organization, 2011.
  3. Nilan K, McNeill A, Murray RL, McKeever TM, Raw M. A survey of tobacco dependence treatment guidelines content in 61 countries. Addiction. 2018; 113(8): 1499-506.
    Pubmed KoreaMed CrossRef
  4. Hwang JS, Lee CM. Recent updates of pharmacotherapy for smoking cessation. Korean J Fam Pract. 2021; 11(6): 403-14.
    CrossRef
  5. Schünemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clinical Epidemiol. 2017; 81: 101-10.
    Pubmed CrossRef
  6. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182(18): E839-E42.
    Pubmed KoreaMed CrossRef
  7. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007; 7(1): 1-7.
    Pubmed KoreaMed CrossRef
  8. Schünemann H BJ, Guyatt G, Oxman A. GRADE Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. [Internet]. Hamilton (Canada); 2013. [cited 2023 May 15]
    Available from: https://gdt.gradepro.org/app/handbook/handbook.html
  9. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update US Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008; 53(9): 1217-22.
  10. Leone FT, Zhang Y, Evers-Casey S, Evins AE, Eakin MN, Fathi J, et al. Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020; 202(2): e5-e31.
    Pubmed KoreaMed CrossRef
  11. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Jr. Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008; 63(8): 717-24.
    Pubmed KoreaMed CrossRef
  12. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016; 387(10037): 2507-20.
    Pubmed CrossRef
  13. de Dios MA, Anderson BJ, Stanton C, Audet DA, Stein M. Project Impact: a pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers. J Subst Abuse Treat. 2012; 43(3): 322-30.
    Pubmed KoreaMed CrossRef
  14. Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial. JAMA. 2016; 315(4): 371-9.
    Pubmed KoreaMed CrossRef
  15. Heydari G, Talischi F, Tafti SF, Masjedi MR. Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. Int J Tuberc Lung Dis. 2012; 16(2): 268-72.
    Pubmed CrossRef
  16. Lerman C, Schnoll RA, Hawk LW, Jr., Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015; 3(2): 131-8.
    Pubmed CrossRef
  17. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, et al. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. Addiction. 2017; 112(10): 1808-20.
    Pubmed CrossRef
  18. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J. 2010; 74(4): 771-8.
    Pubmed CrossRef
  19. Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. BMC Med. 2016; 14: 80.
    Pubmed KoreaMed CrossRef
  20. Tuisku A, Salmela M, Nieminen P, Toljamo T. Varenicline and nicotine patch therapies in young adults motivated to quit smoking: a randomized, placebo-controlled, prospective study. Basic Clin Pharmacol Toxicol. 2016; 119(1): 78-84.
    Pubmed CrossRef
  21. Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation [Internet]. NCT01406223. 2017. [cited 2023 May 15]
    Available from: https://clinicaltrials.gov/ct2/show/NCT01406223
  22. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann‐Boyce J, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019; 4(4): CD013308.
    Pubmed CrossRef
  23. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006; 296(1): 56-63.
    Pubmed CrossRef
  24. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006; 296(1): 47-55.
    Pubmed CrossRef
  25. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013; 70(5): 522-33.
    Pubmed KoreaMed CrossRef
  26. Gray KM, Carpenter MJ, Lewis AL, Klintworth EM, Upadhyaya HP. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. Nicotine Tob Res. 2012; 14(2): 234-9.
    Pubmed KoreaMed CrossRef
  27. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placeboand bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006; 166(15): 1561-8.
    Pubmed CrossRef
  28. The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior [Internet]. 2018. [cited 2023 May 15]
    Available from: https://clinicaltrials.gov/ct2/show/NCT00580853
  29. Shang X, Guo K, Fenfen E, Deng X, Wang Y, Wang Z, et al. Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis. Front Pharmacol. 2022; 13: 1012433.
    Pubmed KoreaMed CrossRef
  30. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med. 2014; 12: 172.
    Pubmed KoreaMed CrossRef
  31. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014; 312(2): 155-61.
    Pubmed CrossRef
  32. Baker TB, Piper ME, Smith SS, Bolt DM, Stein JH, Fiore MC. Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2021; 326(15): 1485-93.
    Pubmed KoreaMed CrossRef
  33. Schnoll R, Leone F, Veluz-Wilkins A, Miele A, Hole A, Jao NC, et al. A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. Psychooncology. 2019; 28(3): 561-9.
    Pubmed KoreaMed CrossRef
  34. Murray RL, Zhang YQ, Ross S, O'Brien KK, Zhu M, Leone FT, et al. Extended Duration Treatment of Tobacco Dependence: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2022; 19(8): 1390-403.
    Pubmed CrossRef
  35. Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007; 82(2): 186-95.
    Pubmed CrossRef
  36. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311(2):145-54.
    Pubmed KoreaMed CrossRef
  37. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med. 2001; 135(6): 423-33.
    Pubmed CrossRef
  38. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006; 296(1): 64-71.
    Pubmed CrossRef
  39. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010; 152(3): 144-51.
    Pubmed KoreaMed CrossRef
  40. Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med. 2015; 175(4): 504-11.
    Pubmed KoreaMed CrossRef
  41. Schlam TR, Fiore MC, Smith SS, Fraser D, Bolt DM, Collins LM, et al. Comparative effectiveness of intervention components for producing long-term abstinence from smoking: a factorial screening experiment. Addiction. 2016; 111(1): 142-55.
    Pubmed KoreaMed CrossRef
  42. Extended varenicline treatment for smoking among cancer patients. [Internet]. 2012. [cited 2023 May 15]
    Available from: https://clinicaltrials. gov/ct2/show/NCT01756885
  43. Bolin K, Mörk AC, Wilson K. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract. 2009; 15(3): 478-85.
    Pubmed CrossRef
  44. Knight C, Marbaix S, Annemans L, Prignot J, Bowrin K. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective. Acta Clin Belg. 2012; 67(6): 416-22.
  45. Dale Horst W, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat. 2005; 1(4): 349-55.
  46. West R. Time for a change: putting the Transtheoretical (Stages of Change) Model to rest. Addiction. 2005; 100(8): 1036-9.
    Pubmed CrossRef
  47. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol. 2002; 22(5): 487-95.
    Pubmed CrossRef
  48. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015; 313(7): 687-94.
    Pubmed KoreaMed CrossRef
  49. Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. Nicotine Tob Res. 2011; 13(10): 955-64.
    Pubmed KoreaMed CrossRef
  50. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res. 2012; 14(3): 343-50.
    Pubmed KoreaMed CrossRef
  51. Evins AE, Benowitz NL, West R, Russ C, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial. J Clin Psychopharmacol. 2019; 39(2): 108-16.
    Pubmed KoreaMed CrossRef
  52. Evins AE, West R, Benowitz NL, Russ C, Lawrence D, McRae T, et al. Efficacy and safety of pharmacotherapeutic smoking cessation aids in schizophrenia spectrum disorders: subgroup analysis of EAGLES. Psychiatr Serv. 2021; 72(1): 7-15.
    Pubmed KoreaMed CrossRef
  53. Ayers CR, Heffner JL, Russ C, Lawrence D, McRae T, Evins AE, et al. Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. Depress Anxiety. 2020; 37(3): 247-60.
    Pubmed KoreaMed CrossRef
  54. Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, Minnix J, et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety. 2022; 39(5): 429-40.
    Pubmed KoreaMed CrossRef
  55. Tønnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013; 22(127): 37-43.
    Pubmed KoreaMed CrossRef
  56. Antoniu SA, Buculei I, Mihaltan F, Crisan Dabija R, Trofor AC. Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review. Expert Opin Pharmacother. 2021; 22(7): 835-47.
    Pubmed CrossRef
  57. Le Mao R, Tromeur C, Paleiron N, Sanchez O, Gagnadoux F, Jouneau S, et al. Effect of Early Initiation of Varenicline on Smoking Cessation in COPD Patients Admitted for Exacerbation: The Save Randomized Clinical Trial. COPD. 2020; 17(1): 7-14.
    Pubmed CrossRef
  58. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001; 357(9268): 1571-5.
    Pubmed CrossRef
  59. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011; 139(3): 591-9.
    Pubmed CrossRef
  60. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006; 130(2): 334-42.
    Pubmed CrossRef
  61. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005; 165(19): 2286-92.
    Pubmed CrossRef